Interleukin-10 polymorphisms, cancer susceptibility and prognosis
W Martin Howell1, Matthew J Rose-Zerilli
1Molecular Pathology Department, Southampton University, Hospitals NHS Trust, Southampton, UK. martin.howell@nbs.nhs.uk
Familial Cancer
|June 1, 2006
Summary
Interleukin-10 (IL-10) gene polymorphisms influence cancer risk and progression, with varying effects depending on cancer type. Further research with larger sample sizes is needed to confirm these associations.
Area of Science:
- Immunology
- Genetics
- Oncology
Background:
- Interleukin-10 (IL-10) is a cytokine with dual roles in cancer, exhibiting both immunosuppressive and anti-angiogenic functions.
- IL-10 gene promoter polymorphisms, particularly single nucleotide polymorphisms (SNPs), are linked to differential IL-10 expression.
- The association between IL-10 polymorphisms and cancer susceptibility/prognosis is an area of active investigation.
Purpose of the Study:
- To review existing studies investigating the association between IL-10 gene polymorphisms and cancer susceptibility and prognosis.
- To synthesize findings across various cancer types and identify trends or conflicting results.
- To highlight the need for larger, more comprehensive studies.
Main Methods:
- Systematic review of 22 studies across 13 different malignancies.
- Analysis of reported associations between IL-10 genotypes/haplotypes and cancer susceptibility/progression.
- Evaluation of conflicting findings, particularly in breast cancer.
Main Results:
- Positive associations between IL-10 polymorphisms and cancer susceptibility/progression were reported in 17 out of 22 studies.
- Genotypes linked to low IL-10 expression were risk factors in some cancers, while high IL-10-associated genotypes were risk factors in others.
- Published data for breast cancer remain conflicting.
Conclusions:
- IL-10 gene polymorphisms appear to play a role in cancer development and progression, but their specific impact varies by cancer type.
- Current evidence is largely based on small sample sizes and limited polymorphism analysis, necessitating larger, more detailed studies.
- Future research should integrate genotype, haplotype, and gene expression data for a comprehensive understanding of IL-10's role in cancer.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...